Cargando…
Therapeutic approaches in myelofibrosis and myelodysplastic/myeloproliferative overlap syndromes
The discovery of JAK2(V617F) a decade ago led to optimism for a rapidly developing treatment revolution in Ph(−) myeloproliferative neoplasms. Unlike BCR–ABL, however, JAK2 was found to have a more heterogeneous role in carcinogenesis. Therefore, for years, development of new therapies was slow, des...
Autores principales: | Sochacki, Andrew L, Fischer, Melissa A, Savona, Michael R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4844455/ https://www.ncbi.nlm.nih.gov/pubmed/27143923 http://dx.doi.org/10.2147/OTT.S83868 |
Ejemplares similares
-
Clinical management of myelodysplastic syndrome/myeloproliferative neoplasm overlap syndromes
por: Clara, Joseph A., et al.
Publicado: (2016) -
Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
por: Komrokji, Rami S., et al.
Publicado: (2022) -
Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Differential Diagnosis in the WHO and ICC 2022 Era: A Focused Review
por: Fontana, Diletta, et al.
Publicado: (2023) -
Myelodysplastic syndromes and overlap syndromes
por: Chang, Yoon Hwan
Publicado: (2021) -
Definitions, Biology, and Current Therapeutic Landscape of Myelodysplastic/Myeloproliferative Neoplasms
por: Gerke, Margo B., et al.
Publicado: (2023)